Bevacizumab in recurrent high-grade pediatric gliomas (Q34133084)

31 July 2017

Bevacizumab in recurrent high-grade pediatric gliomas (English)

1 reference

31 July 2017

1 reference

Ashwatha Narayana

1

1 reference

31 July 2017

Saroj Kunnakkat

2

1 reference

31 July 2017

Jeena Chacko-Mathew

3

1 reference

31 July 2017

Sharon Gardner

4

1 reference

31 July 2017

Matthias Karajannis

5

1 reference

31 July 2017

Shahzad Raza

6

1 reference

31 July 2017

Jeffrey Wisoff

7

1 reference

31 July 2017

Howard Weiner

8

1 reference

31 July 2017

David Harter

9

1 reference

31 July 2017

Jeffrey Allen

10

1 reference

31 July 2017

2 April 2010

1 reference

31 July 2017

1 reference

31 July 2017

12

1 reference

31 July 2017

9

1 reference

31 July 2017

985-990

1 reference

Histology and molecular pathology of pediatric brain tumors

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Pediatric brain tumors: current treatment strategies and future therapeutic approaches

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Bevacizumab for advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940690

28 October 2018

Identifiers

DOI

10.1093/NEUONC/NOQ033

1 reference

31 July 2017

1 reference

31 July 2017

1 reference